Growth Control and Cancer Metastasis

Trip Lab

Desactivado

Dr. Roger Gomis

Group Leader

Telephone:

+34 93 40 39959

Email:

roger.gomis@irbbarcelona.org

ICREA Research Professor

Meet Our Scientists Videos

Roger Gomis: "Light and credibility"

Research information

Background

Intricate signalling networks control cell division, differentiation, movement, organization and death. Understanding how cells read and transform these signals into changes in cell behaviour is a major research focus of our group. Cancer cells disobey these signals during tumour progression and metastasis. Metastasis is the final step in 90% of all fatal solid tumours. It is therefore a grave public health problem and consequently a field of considerable pharmaceutical interest.

Research interests

Growth Control and Cancer Metastasis

Our research centres on how growth factors, signalling pathways, and gene expression programmes control normal cell proliferation and cancer cell metastasis.

We study the ways in which cancer cells evade tumour suppressor mechanisms and engage in metastatic behaviour. We focus on a cytostatic programme involving the transcriptional activation of cell cycle inhibitors and the transcriptional repression of growth-promoting and anti-differentiation factors. Furthermore, we examine how tumour cells evade these gene responses in order to pursue metastatic behaviour. By combining in vivo selection of human metastatic cells, transcriptomic profiling and functional testing, we identify genes that selectively mediate breast metastasis to specific organs. Gene transfer techniques and RNAi-mediated gene silencing are used to functionally validate candidate genes. We are encouraged by the recent validation of these findings in clinical samples. Several of these genes encode products that are susceptible to therapeutic targeting.

Selected publications

ERK1/2 Signaling Induces Upregulation of ANGPT2 and CXCR4 to Mediate Liver Metastasis in Colon Cancer

Urosevic, J; Blasco, MT; Llorente, A; Bellmunt, A; Berenguer-Llergo, A; Guiu, M; Cañellas, A; Fernandez, E; Burkov, I; Clapés, M; Cartanà, M; Figueras-Puig, C; Batlle, E; Nebreda, AR; Gomis, RR

Cancer Research

(21 )

4668 -

4680

(2020)

MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+breast cancer

Gawrzak, S; Rinaldi, L; Gregorio, S; Arenas, EJ; Salvador, F; Urosevic, J; Figueras-Puig, C; Rojo, F; Barrantes, ID; Cejalvo, JM; Palafox, M; Guiu, M; Berenguer-Llergo, A; Symeonidi, A; Bellmunt, A; Kalafatovic, D; Arnal-Estapé, A; Fernández, E; Müllauer, B; Groeneveld, R; Slobodnyuk, K; Attolini, CSO; Saura, C; Arribas, J; Cortes, J; Rovira,...

Nature Cell Biology

(2 )

211 -

(2018)

Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial

Coleman, R; Hall, A; Albanell, J; Hanby, A; Bell, R; Cameron, D; Dodwell, D; Marshall, H; Jean-Mairet, J; Tercero, JC; Rojo, F; Gregory, W; Gomis, RR

Lancet Oncology

(11 )

1543 -

1552

(2017)

FoxA and LIPG endothelial lipase control the uptake of extracellular lipids for breast cancer growth

Slebe, F; Rojo, F; Vinaixa, M; García-Rocha, M; Testoni, G; Guiu, M; Planet, E; Samino, S; Arenas, EJ; Beltran, A; Rovira, A; Lluch, A; Salvatella, X; Yanes, O; Albanell, J; Guinovart, JJ; Gomis, RR

Nature Communications

(11199 )

11199 -

(2016)

Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis

Pavlovic, M; Arnal-Estapé, A; Rojo, F; Bellmunt, A; Tarragona, M; Guiu, M; Planet, E; Garcia-Albéniz, X; Morales, M; Urosevic, J; Gawrzak, S; Rovira, A; Prat, A; Nonell, L; Lluch, A; Jean-Mairet, J; Coleman, R; Albanell, J; Gomis, RR

Jnci-Journal Of The National Cancer Institute

107

(12 )

djv256 -

(2015)

Colon cancer cells colonize the lung from established liver metastases through p38 MAPK signalling and PTHLH

Urosevic, J; Garcia-Albéniz, X; Planet, E; Real, S; Céspedes, MV; Guiu, M; Fernandez, E; Bellmunt, A; Gawrzak, S; Pavlovic, M; Mangues, R; Dolado, I; Barriga, FM; Nadal, C; Kemeny, N; Batlle, E; Nebreda, AR; Gomis, RR

Nature Cell Biology

(7 )

685 -

(2014)

RARRES3 suppresses breast cancer lung metastasis by regulating adhesion and differentiation

Morales, M; Arenas, EJ; Urosevic, J; Guiu, M; Fernández, E; Planet, E; Fenwick, RB; Fernández-Ruiz, S; Salvatella, X; Reverter, D; Carracedo, A; Massagué, J; Gomis, RR

Embo Molecular Medicine

(7 )

865 -

881

(2014)

Projects

"Mecanismos de latencia metastática en cancer de mama" cofinanciado por el Ministerio de Economia y Competitividad y por el Fondo Europeo de Desarrollo Regional (FEDER). Referencia: SAF2016-76008-R (MINECO/FEDER, UE)

"LIPID targeting in breast cancer" Fondo Europeo de Desarrollo Regional (FEDER) de la Unión Europea en el marco del Programa operativo FEDER de Catalunya 2014-2020. Referencia: 2016 PROD 00086

"Metastasis Cell Fate Mapping" La Caixa Foundation under the agreement LCF/PR/HR17/52150014

"Vulnerabilities of Tumour and Stroma Interactions in Castration-Naïve Metastatic Prostate Cancer" Acrónimo: PROSTARGET de la Asociación Española contra el Cáncer (AECC).

"Identificació de mecanismes de resposta als inhibidors de CDK4/6 en càncer de mama receptor hormonal positiu" funded by Fundació La Marató de TV3. Reference: 201935-32

"Redes transcripcionales y diferenciación luminal en la metástasis del cáncer de mama: Una aproximación biológica para tratamientos efectivos" Ministerio de Ciencia e Innovación Reference: PID2019-104948RB-I00

"Deconstructing the evolution of metastasis - EVOMET" European Commission H2020-MSCA-ITN-2020. Grant Agreement: 955951

"Dynamic phenotype adaptation at the core of metastasis biology (AdapMet)" Fundació Asociación Española contra el Cancer AECC. Reference: PRYGN223207GOMI

"Desarrollo de nuevas terápias para el cáncer de mama ER+ resistente a inhibidores de CDK4/6" Ministerio de Ciencia e Innovación MCIN/AEI /10.13039/501100011033 European Union Next GenerationEU/ PRTR. Reference: PDC2022-133289-I00